



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tagraxofusp

Cat. No.:	HY-P99536
CAS No.:	2055491-00-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) ^[1] .								
IC₅₀ & Target	IL-3								
In Vitro	<p>Tagraxofusp (0-1367 pM; 72 h) inhibits pDCs viability, as well as pDC-induced proliferation of MM cells. Tagraxofusp (0-136.7 pM; 2-3 weeks) inhibits osteoclast formation and bone resorption, as well as stabilizes osteoblast formation^[1].</p> <p>Tagraxofusp (0-13.67 nM; 48 h) targets tumor-initiating stem-like cells in MM^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>Cancer stem-like cells in MM</td> </tr> <tr> <td>Concentration:</td> <td>0 nM, 0.013 nM, 0.13 nM, 1.3 nM, 13.67 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibits cancer stem-like cells with s of 30 pM (pDCs), 50 nM (MM-SP-Oct4 cells), 75 pM (RPMI-8226-Oct4 cells), 350 pM (MM-SP cells), and 1367 pM (RPMI-8226 cells), respectively.</td> </tr> </table>	Cell Line:	Cancer stem-like cells in MM	Concentration:	0 nM, 0.013 nM, 0.13 nM, 1.3 nM, 13.67 nM	Incubation Time:	48 hours	Result:	Inhibits cancer stem-like cells with s of 30 pM (pDCs), 50 nM (MM-SP-Oct4 cells), 75 pM (RPMI-8226-Oct4 cells), 350 pM (MM-SP cells), and 1367 pM (RPMI-8226 cells), respectively.
Cell Line:	Cancer stem-like cells in MM								
Concentration:	0 nM, 0.013 nM, 0.13 nM, 1.3 nM, 13.67 nM								
Incubation Time:	48 hours								
Result:	Inhibits cancer stem-like cells with s of 30 pM (pDCs), 50 nM (MM-SP-Oct4 cells), 75 pM (RPMI-8226-Oct4 cells), 350 pM (MM-SP cells), and 1367 pM (RPMI-8226 cells), respectively.								
In Vivo	<p>Tagraxofusp (12-50 µg/kg; i.v.; 5 times per week for 3 weeks) blocks pDC-induced tumor growth and prolongs SCID-hu mice survival in subcutaneous INA-6 MM xenograft model^[1].</p> <p>Tagraxofusp (16 µg/kg; i.v.; 5 times per week for 1 weeks) enhances the anti-MM activity of 2.5 mg/kg Pomalidomide in CB-17 mice of subcutaneous MM xenograft model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>SCID-hu mice with INA-6 MM cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>12 µg/kg, 16 µg/kg, 25 µg/kg and 50 µg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; for 5 consecutive days each week for 3 weeks</td> </tr> </table>	Animal Model:	SCID-hu mice with INA-6 MM cells ^[1]	Dosage:	12 µg/kg, 16 µg/kg, 25 µg/kg and 50 µg/kg	Administration:	Intravenous injection; for 5 consecutive days each week for 3 weeks		
Animal Model:	SCID-hu mice with INA-6 MM cells ^[1]								
Dosage:	12 µg/kg, 16 µg/kg, 25 µg/kg and 50 µg/kg								
Administration:	Intravenous injection; for 5 consecutive days each week for 3 weeks								

Result:	Blocked pDC-induced tumor growth and prolonged mice survival at 12 µg/kg. Showed well tolerance at 16 µg/kg, while higher doses resulted in body weight decrease and toxicity.
Animal Model:	CB-17 mice with subcutaneous MM xenograft model ^[1]
Dosage:	16 µg/kg; with or without 2.5 mg/kg Pomalidomide (p.o.; 4 consecutive days weekly for 2 weeks)
Administration:	Intravenous injection; dose at 5 consecutive days for first week
Result:	Enhanced the anti-MM activity of proteasome inhibitor and immunomodulatory drug pomalidomide.

REFERENCES

[1]. Ray A, et al. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. *Leukemia*. 2017 Dec;31(12):2652-2660.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA